- Email: [email protected]
Ovarian management at the time of radical hysterectomy for cancer of the cervix
Citations from the Literature Ovarian management at the time of radical hysterectomy for cancer of the cervix
Owens S; Roberts WS; Fiorica JV; Hoffman MS; LaPolla Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida College of Medicine, USA GYNECOL ONCOL 1989,35/3 (349-351) Ovarian management at the time of radical hysterectomy for cervical cancer was reviewed retrospectively over a 7-year period. All patients had early-stage cancer except three who had stage IIB disease. Approximately 80% of patients had squamous cancer and 20% adenocarcinoma or adenosquamous carcinoma. The mean age was 44, and 24% of patients were 35 or younger. Ninety-nine patients had their ovaries removed. None of the ovaries contained metastatic disease including 22 patients with adenocarcinoma or adenosquamous carcinoma. Of the 17 patients with retained ovaries 14 had transposition into the paracolic gutters. Only one of the 14 patients with transposed ovaries developed symptoms of ovarian failure. No patients with retained ovaries developed metastatic disease or required reoperation secondary to new ovarian pathology. It is our opinion that normal ovaries can be preserved in young women at the time of radical hysterectomy for early cervical cancer regardless of histologic type.
Use of CA 125 monoclonal antibody to monitor patients
Kudlacek S; Schieder K; Kolbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Furlinger B; Micksche M Institute of Applied and Experimental Oncology, University of Vienna, Vienna, AUT GYNECOL ONCOL 1989,35/3 (323-329) The monoclonal antibody (mAb) OC 125 reacts with an antigen on human ovarian carcinama (OVCA) cells that is also shed into the body fluids and can be detected in patients’ sera and/or ascites with a radioimmunometric assay. For the present study, serum CA 125 levels of patients (n = 36) with different stages of OVCA were investigated. Serum levels seem to correlate with tumor burden. In stages I and II (n = 12), 33qo of patients were CA 125 positive, whereas 70% of stage III and IV patients (n = 24) were CA 125 positive. Mean serum levels were in 93 U/ml (stages I, II) and 279 U/ml (stages III, IV). CA 125 levels in ascites and in pleural effusions were manyfold higher than serum levels of the same patients (P < 0.0001). Immunohistochemical investigations of CA 125 in different ovarian tumors (n = 91) revealed that 85% of malignant and 75% of borderline serous cystadenocarcinomas had detectable CA 125 surface expression. Furthermore, 71% of benign tumors showed the CA 125 epitope, whereas mutinous tumors were negative for this marker. One of six ovarian cancer cell lines was CA 125 positive, whereas in 6 of 11 patients, ascitesderived ovarian cancer cells (fresh and gradient isolated) were positive for this marker. The proportion of positive cells ranged from 10 to 90% in these samples. Intraperitoneal recombinant interferon-gamma (rIFN-gamma) therapy resulted in an increase in the number of cells reacting with CA
399
125. The results of monitoring in patients receiving different therapeutic regimens and/or agents demonstrate the usefulness of this marker. Comparison of short-lived high-LET o-emitting radionuclides lead-212 and bismuth-212 to low-LET X-rays on ovarian carcinoma
Rotmensch J; Atcher RW; Hines J; Toohill M; Herbst Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicage, Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, IL 60637, USA GYNECOL ONCOL 1989,35/3 (297-300) We are investigating the potential use of short-lived a-emitting radionuclides for the treatment of ovarian carcinoma. These radionuclides transfer dense high ionizing linear energy (high LET) over a short path length without dependence upon cellular oxygen. The o-emitting radionuclides chosen were lead-212 and bismuth-212 which are readily available. The radiosensitivity of two ovarian carcinoma cell lines (OVC-1 and OVC-2) was greater with *‘*Pb and ‘12Bithan with X-ray therapy. D,, inversely related to the radiosensitivity, was 155 and 240 rads for OVC-1 and OVC-2, respectively. With 2L2Pb or *12Bi,the slope of the survival curves was steeper. The D, was 75 and 70 rads after 2’1Pb and 85 and 95 rads after 21ZBi treatment for OVC-1 and OVC-2, respectively. The relative biological effectiveness with a irradiation was two to four times greater than X rays. Unlike low-LET irradiation (i.e., X-rays and gamma emitters) the cells had no ability to accumulate or repair sublethal damage. From these experiments it is concluded that a greater therapeutic advantage may be gained with a-emitting radionuclides than X rays. Further development of these nuclides may provide for a new form of therapy. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer
Gerritsen van der Hoop R; Vecht CJ; Van der Burg MEL; Elderson A; Boogerd W; Heimans JJ; Vries EP; Van Houwelingen JC; Jennekens FGI; Gispen WH; Neijt JP Department of Oncology, Utrecht University Hospital, Heidelbergloan 100, 3508 GA Utrecht, NLD NEW ENGL J MED 1990,322/2 (89-94) In a randomized, double-blind, placebo-controlled study, we assessed the efficacy of an ACTH(4-9) analogue, Org 2766, in the prevention of cisplatin neuropathy in 55 women with ovarian cancer. The analogue was given subcutaneously in a dose of 0.25 mg (low dose) or 1 mg (high dose) per square meter of body-surface area before and after treatment with cisplatin and cyclophosphamide (75 and 750 mg per square meter every three weeks). The threshold of vibration perception was used as the principal measure of neurotoxicity. After four cycles of chemotherapy, the mean ( e SEM) threshold value for vibration perception in the placebo group increased from 0.67 + 0.12 to 1.61 f 0.43 pm of skin displacement (P < 0.0081). In the high-dose treatment group, there was no increase in the threshold value after four cycles (from 0.54 f 0.12 to 0.50 2 0.06~m). After six cycles of chemotherapy, the threshold value Int J Gynecol Obstet 32
Owens S; Roberts WS; Fiorica JV; Hoffman MS; LaPolla Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida College of Medicine, USA GYNECOL ONCOL 1989,35/3 (349-351) Ovarian management at the time of radical hysterectomy for cervical cancer was reviewed retrospectively over a 7-year period. All patients had early-stage cancer except three who had stage IIB disease. Approximately 80% of patients had squamous cancer and 20% adenocarcinoma or adenosquamous carcinoma. The mean age was 44, and 24% of patients were 35 or younger. Ninety-nine patients had their ovaries removed. None of the ovaries contained metastatic disease including 22 patients with adenocarcinoma or adenosquamous carcinoma. Of the 17 patients with retained ovaries 14 had transposition into the paracolic gutters. Only one of the 14 patients with transposed ovaries developed symptoms of ovarian failure. No patients with retained ovaries developed metastatic disease or required reoperation secondary to new ovarian pathology. It is our opinion that normal ovaries can be preserved in young women at the time of radical hysterectomy for early cervical cancer regardless of histologic type.
Use of CA 125 monoclonal antibody to monitor patients
Kudlacek S; Schieder K; Kolbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Furlinger B; Micksche M Institute of Applied and Experimental Oncology, University of Vienna, Vienna, AUT GYNECOL ONCOL 1989,35/3 (323-329) The monoclonal antibody (mAb) OC 125 reacts with an antigen on human ovarian carcinama (OVCA) cells that is also shed into the body fluids and can be detected in patients’ sera and/or ascites with a radioimmunometric assay. For the present study, serum CA 125 levels of patients (n = 36) with different stages of OVCA were investigated. Serum levels seem to correlate with tumor burden. In stages I and II (n = 12), 33qo of patients were CA 125 positive, whereas 70% of stage III and IV patients (n = 24) were CA 125 positive. Mean serum levels were in 93 U/ml (stages I, II) and 279 U/ml (stages III, IV). CA 125 levels in ascites and in pleural effusions were manyfold higher than serum levels of the same patients (P < 0.0001). Immunohistochemical investigations of CA 125 in different ovarian tumors (n = 91) revealed that 85% of malignant and 75% of borderline serous cystadenocarcinomas had detectable CA 125 surface expression. Furthermore, 71% of benign tumors showed the CA 125 epitope, whereas mutinous tumors were negative for this marker. One of six ovarian cancer cell lines was CA 125 positive, whereas in 6 of 11 patients, ascitesderived ovarian cancer cells (fresh and gradient isolated) were positive for this marker. The proportion of positive cells ranged from 10 to 90% in these samples. Intraperitoneal recombinant interferon-gamma (rIFN-gamma) therapy resulted in an increase in the number of cells reacting with CA
399
125. The results of monitoring in patients receiving different therapeutic regimens and/or agents demonstrate the usefulness of this marker. Comparison of short-lived high-LET o-emitting radionuclides lead-212 and bismuth-212 to low-LET X-rays on ovarian carcinoma
Rotmensch J; Atcher RW; Hines J; Toohill M; Herbst Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicage, Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, IL 60637, USA GYNECOL ONCOL 1989,35/3 (297-300) We are investigating the potential use of short-lived a-emitting radionuclides for the treatment of ovarian carcinoma. These radionuclides transfer dense high ionizing linear energy (high LET) over a short path length without dependence upon cellular oxygen. The o-emitting radionuclides chosen were lead-212 and bismuth-212 which are readily available. The radiosensitivity of two ovarian carcinoma cell lines (OVC-1 and OVC-2) was greater with *‘*Pb and ‘12Bithan with X-ray therapy. D,, inversely related to the radiosensitivity, was 155 and 240 rads for OVC-1 and OVC-2, respectively. With 2L2Pb or *12Bi,the slope of the survival curves was steeper. The D, was 75 and 70 rads after 2’1Pb and 85 and 95 rads after 21ZBi treatment for OVC-1 and OVC-2, respectively. The relative biological effectiveness with a irradiation was two to four times greater than X rays. Unlike low-LET irradiation (i.e., X-rays and gamma emitters) the cells had no ability to accumulate or repair sublethal damage. From these experiments it is concluded that a greater therapeutic advantage may be gained with a-emitting radionuclides than X rays. Further development of these nuclides may provide for a new form of therapy. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer
Gerritsen van der Hoop R; Vecht CJ; Van der Burg MEL; Elderson A; Boogerd W; Heimans JJ; Vries EP; Van Houwelingen JC; Jennekens FGI; Gispen WH; Neijt JP Department of Oncology, Utrecht University Hospital, Heidelbergloan 100, 3508 GA Utrecht, NLD NEW ENGL J MED 1990,322/2 (89-94) In a randomized, double-blind, placebo-controlled study, we assessed the efficacy of an ACTH(4-9) analogue, Org 2766, in the prevention of cisplatin neuropathy in 55 women with ovarian cancer. The analogue was given subcutaneously in a dose of 0.25 mg (low dose) or 1 mg (high dose) per square meter of body-surface area before and after treatment with cisplatin and cyclophosphamide (75 and 750 mg per square meter every three weeks). The threshold of vibration perception was used as the principal measure of neurotoxicity. After four cycles of chemotherapy, the mean ( e SEM) threshold value for vibration perception in the placebo group increased from 0.67 + 0.12 to 1.61 f 0.43 pm of skin displacement (P < 0.0081). In the high-dose treatment group, there was no increase in the threshold value after four cycles (from 0.54 f 0.12 to 0.50 2 0.06~m). After six cycles of chemotherapy, the threshold value Int J Gynecol Obstet 32